Th1/Th2/Th17/Treg cytokines in Guillain-Barré syndrome and experimental autoimmune neuritis
- PMID: 23791985
- DOI: 10.1016/j.cytogfr.2013.05.005
Th1/Th2/Th17/Treg cytokines in Guillain-Barré syndrome and experimental autoimmune neuritis
Abstract
Guillain-Barré syndrome (GBS) is an immune-mediated acute inflammatory disorder in the peripheral nervous system (PNS) of humans characterized by inflammatory infiltration and damage to myelin and axon. Experimental autoimmune neuritis (EAN) is a useful animal model for GBS. Although GBS and EAN have been widely studied, the pathophysiological basis of GBS/EAN remains largely unknown. Immunocompetent cells together with cytokines produced by various cells contribute to the inflammatory process of EAN by acting as mediators or effectors. Both GBS and EAN have hitherto been attributed to T helper (Th)1 cells-mediated disorders, however, some changes in GBS and EAN could not be explained by the pathogenic role of Th1 cells and a disturbance of the Th1/Th2 balance, which has previously been considered to be important for the homeostatic maintenance of the immune responses and to explain the adaptive immunity and autoimmune diseases. The Th1/Th2 paradigm in autoimmune diseases has been greatly challenged in recent years, with the identification of a particular T cell subset Th17 cells. Studies on the associations between Th17 cells/cytokines and GBS/EAN are reviewed. But some of them occasionally yield conflicting results, indicating an intricate network of cytokines in immune response.
Keywords: Cytokine; Experimental autoimmune neuritis; Guillain–Barré syndrome; T helper cell; Th17 cell.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Similar articles
-
Mitigated Tregs and augmented Th17 cells and cytokines are associated with severity of experimental autoimmune neuritis.Scand J Immunol. 2014 Sep;80(3):180-90. doi: 10.1111/sji.12201. Scand J Immunol. 2014. PMID: 24910360
-
Are Th17 cells and their cytokines a therapeutic target in Guillain-Barré syndrome?Expert Opin Ther Targets. 2016;20(2):209-22. doi: 10.1517/14728222.2016.1086751. Epub 2015 Sep 10. Expert Opin Ther Targets. 2016. PMID: 26357850 Review.
-
Can IFN-γ be a therapeutic target in Guillain-Barré syndrome?Expert Opin Ther Targets. 2014 Apr;18(4):355-63. doi: 10.1517/14728222.2014.882899. Epub 2014 Jan 30. Expert Opin Ther Targets. 2014. PMID: 24479493 Review.
-
IFN-γ deficiency exacerbates experimental autoimmune neuritis in mice despite a mitigated systemic Th1 immune response.J Neuroimmunol. 2012 May 15;246(1-2):18-26. doi: 10.1016/j.jneuroim.2012.02.011. Epub 2012 Mar 23. J Neuroimmunol. 2012. PMID: 22445739
-
Atorvastatin ameliorates experimental autoimmune neuritis by decreased Th1/Th17 cytokines and up-regulated T regulatory cells.Cell Immunol. 2011;271(2):455-61. doi: 10.1016/j.cellimm.2011.08.015. Epub 2011 Aug 23. Cell Immunol. 2011. PMID: 21889126
Cited by
-
Alnus Sibirica Extracts Suppress the Expression of Inflammatory Cytokines Induced by Lipopolysaccharides, Tumor Necrosis Factor-α, and Interferon-γ in Human Dermal Fibroblasts.Molecules. 2019 Aug 8;24(16):2883. doi: 10.3390/molecules24162883. Molecules. 2019. PMID: 31398908 Free PMC article.
-
Fingolimod attenuates experimental autoimmune neuritis and contributes to Schwann cell-mediated axonal protection.J Neuroinflammation. 2017 Apr 26;14(1):92. doi: 10.1186/s12974-017-0864-z. J Neuroinflammation. 2017. PMID: 28446186 Free PMC article.
-
COVID-19 as a trigger of Guillain-Barré syndrome: A review of the molecular mechanism.Immun Inflamm Dis. 2023 May;11(5):e875. doi: 10.1002/iid3.875. Immun Inflamm Dis. 2023. PMID: 37249286 Free PMC article. Review.
-
Identifying potential co-expressed genes and molecular mechanisms linking post-COVID-19 and Guillain-Barre syndrome through neutrophil extracellular trap-related genes.Front Neurol. 2025 May 13;16:1447725. doi: 10.3389/fneur.2025.1447725. eCollection 2025. Front Neurol. 2025. PMID: 40433617 Free PMC article.
-
Case report and brief literature review: possible association of secukinumab with Guillain-Barré syndrome in psoriasis.Front Immunol. 2024 Jun 28;15:1412470. doi: 10.3389/fimmu.2024.1412470. eCollection 2024. Front Immunol. 2024. PMID: 39007153 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical